secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001104659-25-071413
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q2 ARCALYST revenue $156.8M (+52% YoY); raises 2025 guidance to $625-640M
--------------------------------------------------------------------------------

- ARCALYST net product revenue $156.8M in Q2 2025, up 52% from $103.4M in Q2 2024 (excl. $5.2M license revenue).
- 2025 ARCALYST net revenue guidance raised to $625-640M from prior $590-605M, reflecting continued commercial execution.
- Net income of $17.8M in Q2 2025 vs net loss of $3.9M in Q2 2024; cash and investments $307.8M, no debt.
- KPL-387 Phase 2/3 trial in recurrent pericarditis recruiting; Phase 2 data expected in 2H 2026.
- Approximately 15% of target 14,000 multiple-recurrence pericarditis patients currently on ARCALYST.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925071413/0001104659-25-071413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925071413/tm2521890d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-071413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer